AnGes, Inc (AMGXF) fair value: what the stock is really worth
As of Nov 13, 2026: fair value (intrinsic value) of AnGes, Inc stock $0.23, price $0.17, upside +38.1%, quality 40 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
AnGes, Inc
AMGXF · USCheap enough by our rule, but weak company.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.
How to read this chart
60‑month range $0.1574 – $5.40 · fair‑value band $0.1752 – $0.2920 · the $0.1691 price screens below the $0.2336 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.
Every Wednesday you see whether AnGes is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
AnGes, Inc. engages in the research and development of gene-based medicines.
Show moreShow less
It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B. AnGes, Inc. was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017.
The company was incorporated in 1999 and is headquartered in Ibaraki, Japan.
Stock analysis
AnGes, Inc (AMGXF) currently trades at $0.1691, while our estimate is $0.2336, so the stock looks roughly fairly valued today (gap 27.6%).
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $0.1752 (bear) to $0.2920 (bull), the price of $0.1691 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
AnGes, Inc reported revenue of ¥874M in FY2025 versus ¥64.1M in FY2021, a compound +92.1%/yr. Reported net income was −¥5.1B in FY2025.
Key figures
Market cap $144M Micro · P/S ratio 0.15 · EPS (TTM) $−0.7900 · Return on equity −215% · Return on assets (EBIT) −81.4% (5-year average) · Operating margin −582% · Revenue (TTM) ¥962M · Revenue growth (YoY) +22.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).
What moves the price
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 38%, AMGXF screens cheaper than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Watch AMGXF, get fair value alerts →
Compare AnGes, Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Fair value gap by industry
- Return on assets by industry
- Stock screener with 62 metrics
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $955.47 | $1,275 | +33% | vs AMGXF |
| Vertex Pharmaceuticals Incorporated VRTX | $538.60 | $592.46 | +10% | vs AMGXF |
| Samsung Biologics Co 207940 | 1,411,000 KRW | 1,552,100 KRW | +10% | vs AMGXF |
| Genmab A/S GMAB | kr 3,448 | kr 3,793 | +10% | vs AMGXF |
| argenx SE ARGX | $960.04 | $908.40 | −5% | vs AMGXF |
| CSL Limited CSL | A$202.52 | A$185.51 | −8% | vs AMGXF |
| Moderna, Inc MRNA | $223.37 | $139.99 | −37% | vs AMGXF |
| Revolution Medicines, Inc RVMD | $172.29 | $88.78 | −48% | vs AMGXF |
| Celltrion, Inc 068270 | 214,000 KRW | 74,945 KRW | −65% | vs AMGXF |
| Royalty Pharma plc RPRX | $69.31 | $19.01 | −73% | vs AMGXF |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is AnGes, Inc (AMGXF) overvalued or undervalued?
What is the fair value of AMGXF?
What is the quality score of AMGXF?
What is the price target for AnGes, Inc (AMGXF)?
What is the AnGes, Inc stock forecast for 2026?
What is the revenue of AnGes, Inc (AMGXF)?
What is the intrinsic value of AnGes, Inc (AMGXF)?
Is AnGes, Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of AMGXF?
How much is AnGes, Inc worth?
What do the bullish and bearish scenarios say about AMGXF?
How solid is the balance sheet of AnGes, Inc (AMGXF)?
Which stocks are comparable to AnGes, Inc?
Is AnGes, Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of AnGes, Inc (AMGXF)?
What should I pay attention to with AnGes, Inc right now?
Key figures of AnGes, Inc
How large is the market capitalisation of AnGes, Inc (AMGXF)?
What is the P/S ratio of AnGes, Inc (AMGXF)?
What are the earnings per share of AnGes, Inc (AMGXF)?
What is the return on equity of AnGes, Inc (AMGXF)?
What is the EBIT return on assets of AnGes, Inc (AMGXF)?
What is the operating margin of AnGes, Inc (AMGXF)?
How fast is revenue growing at AnGes, Inc (AMGXF)?
How much free cash flow does AnGes, Inc (AMGXF) generate?
Watch AnGes, Inc in the live analysis
One click puts AnGes, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.